Karolin Behringer
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
Kreissl S, Borchmann P, Engert A, Diehl V, Fuchs M, Flechtner H, Rueffer J, Shonukan O, Soekler M, Hitz F, Halbsguth T, Behringer K, Brillant C, Mayer A, Goergen H, Mueller H. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol 2016; 17:1453-1462.
06.09.2016Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
06.09.2016Lancet Oncol 2016; 17:1453-1462
Kreissl Stefanie, Borchmann Peter, Engert Andreas, Diehl Volker, Fuchs Michael, Flechtner Hans-Henning, Rueffer Jens Ulrich, Shonukan Oluwatoyin, Soekler Martin, Hitz Felicitas, Halbsguth Teresa Veronika, Behringer Karolin, Brillant Corinne, Mayer Axel, Goergen Helen, Mueller Horst
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Böll B, Engert A, Diehl V, Fuchs M, Borchmann S, Bürkle C, Eichenauer D, von Tresckow B, Greil R, Kerkhoff A, Hitz F, Bröckelmann P, Behringer K, Goergen H, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127:2189-92.
01.02.2016Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
01.02.2016Blood 2016; 127:2189-92
Böll Boris, Engert Andreas, Diehl Volker, Fuchs Michael, Borchmann Sven, Bürkle Carolin, Eichenauer Dennis A, von Tresckow Bastian, Greil Richard, Kerkhoff Andrea, Hitz Felicitas, Bröckelmann Paul J, Behringer Karolin, Goergen Helen, Borchmann Peter
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Behringer K, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause S, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, Bentz M, Vieler T, Kriz J, Goergen H, Tanner A, Zijlstra J, Greil R, Markova J, Sasse S, Fuchs M, Topp M, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2014; 385:1418-27.
22.12.2014Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
22.12.2014Lancet 2014; 385:1418-27
Behringer Karolin, Lange Elisabeth, Mahlberg Rolf, Hassler Andre, Vogelhuber Martin, Hahn Dennis, Mezger Jörg, Krause Stefan W, Skoetz Nicole, Böll Boris, von Tresckow Bastian, Diehl Volker, Hallek Michael, Borchmann Peter, Stein Harald, Eich Hans, Engert Andreas, Bentz Martin, Vieler Tom, Kriz Jan, Goergen Helen, Tanner Antonia, Zijlstra Josée M, Greil Richard, Markova Jana, Sasse Stephanie, Fuchs Michael, Topp Max S, Soekler Martin, Mathas Stephan, Meissner Julia, Wilhelm Martin, Koch Peter, Lindemann Hans-Walter, Schalk Enrico, Semrau Robert